Commentary to “Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec” by Kawaguchi et al. Diabetes Therapy 2019
Open Access
- 10 January 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Diabetes Therapy
- Vol. 11 (2), 561-567
- https://doi.org/10.1007/s13300-019-00755-3
Abstract
No abstract availableFunding Information
- Novo Nordisk
This publication has 7 references indexed in Scilit:
- Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin DegludecDiabetes Therapy, 2019
- Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in RangeDiabetes Care, 2019
- Efficacy and safety of insulin glargine 300 U/mL vs insulin degludec in patients with type 2 diabetes: A randomized, open‐label, cross‐over study using continuous glucose monitoring profilesJournal of Diabetes Investigation, 2018
- Morning administration of 0.4 U/kg/day insulin glargine 300 U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100 U/mL in type 1 diabetesDiabetes & Metabolism, 2018
- Efficacy and Safety of Degludec versus Glargine in Type 2 DiabetesThe New England Journal of Medicine, 2017
- Insulin degludec: Lower day‐to‐day and within‐day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetesDiabetes, Obesity and Metabolism, 2017
- Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargineExpert Opinion on Drug Metabolism & Toxicology, 2015